Pharmaceutical planning Signed enterprise engagement
When the demand plan changes, can production actually follow?
A fast-growing Indian pharmaceutical manufacturer signed UpSynQ for integrated business planning: one connected workflow from the demand plan to a production plan its plants can run.
The decision
Every month, sales and marketing move the demand plan. The question that matters is not whether the new number is right — it is whether stock, sources, materials and plant lines can deliver it, and what has to change if they can't.
The programme connects demand review, commercial consensus, central requirement planning, material readiness and plant feasibility into one governed decision flow. Each step changes what the next team can commit to. The hard part is keeping those assumptions, quantities, exceptions and approvals consistent from the first forecast to the production plan.
Why it is hard
- Not all stock is stock. Quantities in QA hold or close to expiry are visible but can't be counted against demand.
- Supply comes in shapes. Batch sizes, minimum order quantities and source-specific lead times turn a requirement into whole batches.
- Capacity alone isn't eligibility. A site with spare capacity is no option if the product isn't qualified there.
- Materials gate the start date. A batch can't begin until raw and packaging materials are released by quality control.
- Rules carry history. Priority tiers, packaging versions, validated lines and staged approvals all decide what is allowed.
Decision trail Illustrative · synthetic numbers
- Demand & consensusStatistical 50.0k → commercial +20% → consensus 60.0k a month, flagged for the approver
- Net requirement57.0k of 70.0k units usable after QA hold and short expiry → 123.0k to plan
- Sourcing & materialPrimary plant eligible; material lots released on days 1, 7 and 16
- Production planFive 25.0k batches on one validated line, days 1–24
- Review & releasePlanner → planning lead → approver; the frozen version goes to the plant